VIDEO: Tirzepatide’s approval for obstructive sleep apnea highlights need for screening
NATIONAL HARBOR, Md. — There is a need to identify patients with obstructive sleep apnea after a weight-loss drug was approved for treatment of the disorder in those with obesity, a speaker said.
VIDEO: Nutrition, exercise may help preserve muscle mass during GLP-1 receptor agonist use
NATIONAL HARBOR, Md. — GLP-1 receptor agonists are effective weight-loss medications, but they may also decrease muscle mass, raising concerns about the long-term effects of these drugs, according to Christos S. Katsanos, PhD.
VIDEO: Anti-obesity drugs in the pipeline
NATIONAL HARBOR, Md. — In this video at Obesity Medicine 2025, Harold E. Bays, MD, FOMA, FTOS, FACC, FASPC, FNLA, discusses highlights from his talk on anti-obesity medications in the pipeline.
Obesity drug coverage could lead to ‘substantial’ increase in Medicare spending
Medicare Part D coverage of obesity medications could lead to a large increase in health care costs due to the prices of the drugs, according to data from a microsimulation model published in JAMA Health Forum.
Long-term weight regain minimal with tirzepatide for adults with obesity, prediabetes
Adults with overweight or obesity plus prediabetes maintain most of their weight loss with tirzepatide at more than 3 years, according to data from two European Congress on Obesity abstracts.
PCPs need to be ‘familiar with and skilled in’ GLP-1 prescribing as use rises in US
Dispensations of tirzepatide and semaglutide increased significantly in recent years while the use of other glucose-lowering and weight-lowering therapies declined, an analysis showed.
Nutrition, exercise guidance with use of obesity medication may help protect muscle mass
Adults with obesity who used medication and received guidance on resistance training and nutrition lost substantially more fat mass than muscle mass, researchers reported in data that will be presented at the European Congress on Obesity.
CMS decision to remove obesity drug coverage from 2026 final rule disappoints societies
A decision by CMS to not move forward with a proposed rule allowing obesity medications to be covered under Medicare Part D has several medical societies advocating for change.
Q&A: Weight-loss drugs may help patients ‘catch up’ if behavioral therapy fails
Adding an anti-obesity medication alongside behavioral therapy produced significantly more weight loss in patients who initially struggled with the therapy, a study in Nature Medicine showed.
Setmelanotide leads to significant decrease in BMI for patients with hypothalamic obesity
A group of children and adults with hypothalamic obesity receiving setmelanotide for 1 year had nearly a 20% greater BMI reduction than those receiving placebo, according to top-line results released by Rhythm Pharmaceuticals.